Summit on Biosimilars & Innovator Biologics

23 September 2020 - 24 September 2020
Hosted By: ACI

Associate Director Dr. Sheng Li and former Senior Consultant Dr. Omar Robles will speak at the virtual ACI 11th Summit on Biosimilars & Innovator Biologics. Dr. Li will participate on the panel titled “Tracking Changes in the BPCIA Antitrust Ecosystem: Regulatory Enforcement, Litigation, Settlements and New Economic Considerations” on 24 September at 11:00 am EDT. He will cover the FTC’s increased interest in biosimilar settlements, potential antitrust implications of at-risk launches, and exclusivity and acceleration provisions.

Dr. Robles will speak on the panel titled, “Pre-Suit Exchanges and the BPCIA Tango: Production, Timing, and the Notice of Commercial Marketing” on 23 September at 3:00 pm EDT. Dr. Robles will address the contentions and controversies in the aBLA information exchange and analyze the biosimilar and innovator perspectives when deciding “whether to dance.”

For more information and to register, please visit ACI’s website here

To contact us about this event, please click here.